Our lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. Read the ataluren overview to learn more.

Ataluren for nmDMD:  Phase 3 study (041), not yet recruiting
More information on this trial can be found at clinicaltrials.gov

Additional information about ataluren clinical trials can be found at Clinicaltrials.gov or by contacting Patient and Professional Advocacy at (866) 282-5873, (908) 912-9256 or PatientInfo@ptcbio.com

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue